Navigation Links
New needle-free HPV vaccine increases effectiveness, availability in developing world
Date:11/17/2010

Arlington, Va. New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

HPV is the number one cause of cervical cancer, which is the second most common cancer in women around the globe. According to the World Health Organization, nearly a quarter of a million women die each year from cervical cancer, 80 percent of them in developing countries.

Lead researcher David McAdams and colleagues from the University of Colorado at Boulder created a dry powder that goes directly to the mucous membranes in the respiratory tract or mouth. Since HPV is a disease that affects the mucous membranes, the powder is more targeted. "Imagine the vaccine as a car," said McAdams. "Using this delivery method is similar to parking in your driveway instead of driving around the block a few times to find a spot."

The dry powder has added benefits for developing countries. For example, the current HPV vaccine is delivered by a needle injection, which is highly susceptible to contamination. The powder, as a solid, rather than a frozen liquid, may be more stable than current HPV vaccines, which makes it easier to store and transport in developing countries.

"While there are effective HPV vaccines on the market, cost, refrigeration and needle disposal shorten the reach they have," commented McAdams. "Our goal is to develop an economical, safe and easily administered HPV vaccine for everyone."

For the first time, FIP's PSWC and the AAPS Annual Meeting and Exposition will join to hold the world's largest pharmaceutical sciences meeting to improve global health through advances in pharmaceutical sciences. An estimated 10,000 scientists from more than 60 countries will participate in 100 sessions, including 40 symposia and roundtables.


'/>"/>

Contact: Joseph Catapano
catapanoJ@aaps.org
703-248-4772
American Association of Pharmaceutical Scientists
Source:Eurekalert

Related biology news :

1. New low-cost method to deliver vaccine shows promise
2. Consortium to design human trials of mosaic HIV vaccine
3. Cow vaccines go vroom
4. Doctors not strongly encouraging HPV vaccine to girls of certain age
5. Scientists use computer algorithms to develop seasonal flu vaccines
6. 2009 H1N1 vaccine protects against 1918 influenza virus
7. New discovery could aid development of elusive bovine mastitis vaccine
8. New bacterial signaling molecule could lead to improved vaccines
9. MSU researchers testing vaccine to help people quit smoking
10. New steps toward a universal flu vaccine
11. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
Breaking Biology Technology: